Bayer announces positive results from phase III QUASAR study of aflibercept 8 mg in patients with macular edema following retinal vein occlusion: Berlin Thursday, December 19, 202 ...
Bayer announced today initiation of a Phase I clinical trial with BAY3498264, an investigational oral selective Son of Sevenless Homologue 1 (SOS1) inhibitor. The open-label, first-in-human, dose ...